Pyrazole-3-carboxamide derivatives for selective 5-HT2B receptor antagonism
Solution Overview
Problem
Current 5-HT 2B receptor antagonists have limitations in selectivity and efficacy, leading to unfavorable side effects and reduced therapeutic benefits for various diseases associated with serotonin receptor stimulation.
Innovation Solution
Development of novel pyrazole-3-carboxamide derivatives with a unique chemical structure that exhibit strong and selective antagonistic activity against the 5-HT 2B receptor, effectively inhibiting visceral pain and other disease-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current 5-HT 2B receptor antagonists are used, then therapeutic benefits are achieved, but selectivity is limited leading to unfavorable side effects
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: a pyrazole-3-carboxamide core structure provides selective 5-HT2B receptor binding, while specific substituent groups (R1-R6 positions) are optimized to enhance selectivity and reduce off-target effects. This localized functional differentiation allows the compound to achieve therapeutic benefits while minimizing side effects associated with non-selective antagonists.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations on the pyrazole core) to optimize receptor selectivity. By adjusting these molecular parameters, the compound achieves enhanced 5-HT2B selectivity compared to existing antagonists, thereby improving the therapeutic index and reducing unfavorable side effects.
2Reliability
If current 5-HT 2B receptor antagonists are used, then disease treatment is achieved, but efficacy is reduced due to lack of selectivity
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the pyrazole-3-carboxamide core provides baseline 5-HT2B affinity, while specific substituent groups at defined positions (R1-R6) are engineered to enhance selectivity. This segmented design allows independent optimization of binding affinity and selectivity, achieving improved disease treatment efficacy.
3Adaptability or versatility
If non-selective serotonin receptor antagonists are used, then broad receptor coverage is achieved, but unfavorable actions increase
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating the specific 5-HT2B receptor binding functionality from the broader serotonin receptor family. The pyrazole-3-carboxamide structure is designed to selectively target 5-HT2B while avoiding significant interaction with other serotonin subtypes (5-HT1, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7), thereby maintaining useful receptor coverage while eliminating unfavorable actions associated with non-selective antagonism.
Data Source
Figure 1

AI summary
Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT2B receptor.
